Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Glioblastoma cells can 'unstick' from their neighbors to become more deadly

2.

Minimally invasive prostate cancer treatment shows success in first patient

3.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

4.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

5.

Cancerous breast tissue glows in new AI-enhanced MRI images


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot